Amantadine in Parkinson's disease. Review of more than two years' experience.
D000368:Aged; D000547:Amantadine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001259:Ataxia / Q000139:chemically induced; D003248:Constipation / Q000139:chemically induced; D003863:Depression / Q000139:chemically induced; D003967:Diarrhea / Q000139:chemically induced; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage; D004357:Drug Synergism; D005069:Evaluation Studies as Topic; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000008:administration & dosage; D010300:Parkinson Disease / Q000188:drug therapy*; D013997:Time Factors; D014202:Tremor / Q000139:chemically induced
D010276:Parasympatholytics; D004295:Dihydroxyphenylalanine; D000547:Amantadine